目的：探讨该地区肺腺癌患者表皮生长因子受体（EGFR）基因19、21号外显子突变情况及其在不同人群中的分布差异。方法收集该院2013年4月至2014年9月109例肺腺癌患者相关标本，应用突变特异性扩增系统‐聚合酶链式反应（ARMS‐PCR）对标本EGFR基因外显子19、21号进行检测。结果109例患者中，19、21号外显子突变56例（51．38％），其中19号外显子突变24例（22．02％），21号外显子突变33例（30．28％）；男性共59例，突变型19例（32．20％），女性50例，突变型37例（74．00％）；大于或等于60岁患者64例，突变型34例（53．13％），小于60岁患者45例，突变型22例（48．89％）；男性吸烟者33例，突变型7例（21．21％），非吸烟者25例，突变型12例（48．00％）。结论该地区肺腺癌患者EGFR基因19、21号外显子总突变率较高，21号外显子突变率稍高于19号外显子，但差异无统计学意义（ P＞0．05）；突变类型及突变率与性别、吸烟史相关，与年龄不相关。%Objective To investigate the 19 and 21 exon mutation status of the epidermal growth factor receptor(EGFR) gene in the patients with lung adenocarcinoma and its distribution differences among different groups .Methods The related samples in 109 cases of lung adenocarcinoma were collected in our hospital during 2013-2014 .The 19 and 21 exons of EGFR gene were detected by adopting the ARMS‐PCR method .Results Among 119 cases ,19 and 21 exons mutations were found in 56 cases(51 .38% ) ,in which 24 cases (22 .02% ) were in exon 19 and 33 cases (30 .28% ) were in exon 21 .59 cases were male with 19 cases(32 .20% ) of mutant type and 50 cases were female with 37 cases (74 .00% ) of mutant type;64 cases were ≥ 60 years old with 34 cases (53 .13% ) of mutant type ,45 cases were <60 years old with 22 cases(48 .89% ) of mutant type;33 male cases were smoking with 7 cases(21 .21% ) of mutant type and 25 male cases were non‐smoking with 12 cases (48 .00% ) of mutant type .Conclusion The 19 and 21 exon mutation rate of EGFR gene in the patients with lung adenocarcinoma is higher in this area ,the 21 exon mutation rate is slightly higher than that of 19 exon;the mutation type and mutation rate are correlated with sex and smoking history ,but have no correlation with age .
展开▼
